53292-90-3

Basic information

• Product Name: CIS-4-(BOC-AMINO)CYCLOHEXANECARBOXYLIC ACID
• Synonyms: cis-1-(t-butyloxycarbonyl-amino)-cyclohexyl-4-carboxylicacid;(1s,4s)-4-(tert-butoxycarbonylamino)cyclohexanecarboxylic acid;trans-4-tert-butoxycarbonylaMinocyclohexane-1-ylcarboxylic acid;cis-4-[(tert-Butyloxycarbonyl)amino]cyclohexanecarboxylic acid;cis-4-[[[(1,1-Dimethylethyl)oxy]carbonyl]amino]cyclohexanecarboxylic acid;cis-4-tert-Butoxycarbonylamino-1-cyclohexanecarboxylic acid;N-BOC-cis-4-Aminocyclohexane-1-carboxylic acid;cis-4-(tert-Butoxycarbonylamino)cyclohexanecarboxylic Acid
• CAS NO: 53292-90-3
• Molecular Formula: C₁₂H₂₁NO₄
• Molecular Weight: 243.3
• Product Categories: Alicyclic Amino Acids;Peptide Synthesis;Unnatural Amino Acid Derivatives
• Mol File: 53292-90-3.mol
• Article Data: 27

Chemical Properties

• Melting Point: 169°C(lit.)
• Boiling Point: 396.698 °C at 760 mmHg
• Flash Point: 193.716 °C
• Appearance: White to off-white/Powder
• Density: 1.13 g/cm³
• Vapor Pressure: 2.12E-07mmHg at 25°C
• Refractive Index: 1.493
• Storage Temp.: 2-8°C
• PKA: 4.89±0.25(Predicted)
• BRN: 7641071
• CAS DataBase Reference: CIS-4-(BOC-AMINO)CYCLOHEXANECARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: CIS-4-(BOC-AMINO)CYCLOHEXANECARBOXYLIC ACID(53292-90-3)
• EPA Substance Registry System: CIS-4-(BOC-AMINO)CYCLOHEXANECARBOXYLIC ACID(53292-90-3)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 53292-90-3(Hazardous Substances Data)

Usage

Chemical Properties

White powder

InChI:InChI=1/C12H21NO4/c1-12(2,3)17-11(16)13-9-6-4-8(5-7-9)10(14)15/h8-9H,4-7H2,1-3H3,(H,13,16)(H,14,15)/t8-,9+

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 1776-53-0 trans-4-aminocyclohexanecarboxylic acid 
• 150-13-0 4-amino-benzoic acid 
• 146307-51-9 methyl (1R,4R)-4-((tert-butoxycarbonyl)amino)cyclohexane-1-carboxylate 
• 603130-12-7 1,5-anhydro-2-[(tert-butoxycarbonyl)amino]-2,3,4-trideoxy-D-erythro-hexitol 
• 881657-40-5 tert-butyl ((3R,6S)-6-formyltetrahydro-2H-pyran-3-yl)carbamate 
• 400899-07-2 methyl (1r,4r)‐4‐{[(tert‐butoxy)carbonyl](methyl)amino}cyclohexane‐1‐carboxylate 
• 38446-95-6 4-oxocyclohexanecarboxylic acid tert-butyl ester 
• 6297-22-9 4-carbomethoxycyclohexanone 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 3685-23-2 cis-4-aminocyclohexane-1-carboxylic acid 
• 1776-53-0 4-aminocyclohexanecarboxylic acid 

Downstream Products

• 133075-92-0 N<carbonyl>phenylalanine benzyl ester 
• 146307-51-9 methyl (1R,4R)-4-((tert-butoxycarbonyl)amino)cyclohexane-1-carboxylate 
• 400898-94-4 trans-(4-formylcyclohexyl)methylcarbamic acid tert-butyl ester 
• 400899-08-3 tert-butyl ((1r,4r)-4-(hydroxymethyl)cyclohexyl)(methyl)carbamate 
• 400899-07-2 methyl (1r,4r)‐4‐{[(tert‐butoxy)carbonyl](methyl)amino}cyclohexane‐1‐carboxylate 
• 400899-12-9 methyl-[4-(3-oxo-propyl)-cyclohexyl]-carbamic acid tert-butyl ester 
• 400899-11-8 [4-(3-hydroxy-propyl)-cyclohexyl]-methyl-carbamic acid tert-butyl ester 
• 400899-10-7 3-[4-(tert-butoxycarbonyl-methyl-amino)-cyclohexyl]-propionic acid ethyl ester 
• 400899-16-3 [4-(5-hydroxy-pentyl)-cyclohexyl]-methyl-carbamic acid tert-butyl ester 
• 400899-17-4 methanesulfonic acid 5-[4-(tert-butoxycarbonyl-methyl-amino)-cyclohexyl]-pentyl ester 

Relevant articles and documents

PYRIMIDINYL GROUP-CONTAINING TRICYCLIC COMPOUND SERVING AS C-MET INHIBITOR

Disclosed are a pyrimidinyl group-containing tricyclic compound and applications thereof in preparing a cancer-treating medicament. Specifically disclosed are a compound as represented by formula (I), a pharmaceutically acceptable salt of same, or an isomer thereof.

BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF

The present disclosure provides bifunctional compounds as IRAK4 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by IRAK4.

Discovery of Hydroxyamidine Derivatives as Highly Potent, Selective Indoleamine-2,3-dioxygenase 1 Inhibitors

In this study, a series of novel hydroxyamidine derivatives were identified as potent and selective IDO1 inhibitors by structure-based drug design. Among them, compounds 13-15 and 18 exhibited favorable enzymatic and cellular activities. Compound 18 showed improved bioavailability in mouse, rat, and dog (F% = 44%, 58.8%, 102.1%, respectively). With reasonable in vivo pharmacokinetic properties, compound 18 was further evaluated in a transgenic MC38 xenograft mouse model. The combination of compound 18 with PD-1 monoclonal antibody showed a synergistic antitumor effect. These data indicated that compound 18 as a potential cancer immunotherapy agent should warrant further investigation.